2018 ESOC | George Research Projects Unveiled on the International Stage

In 2018, the 4th European Stroke Organization Conference (ESOC) was held successfully in Gothenburg, Sweden during 16 to 18 May. Over 4,500 experts, scholars and health professionals in the field of stroke from 90 countries gathered on a record scale for this conference.  This included 85 people registered from China.  Several members of The George Institute China, led by Executive Director Professor Craig Anderson, were invited to the conference and made keynote speeches and poster communications. 

In the blood pressure management session, Professor Anderson gave a keynote speech entitled “New treatment strategies: low-dose antihypertensive combination drugs”, focusing on the research background, rationale and design of the new TRIDENT project.  TRIDENT is the world’s first blood pressure control study for the secondary prevention of patients who suffer a cerebral hemorrhage, aimed at determining the effectiveness of a combination of multiple low-dose antihypertensive drugs to prevent recurrence of stroke, heart attacks and improve survival.  This study attracted the attention of experts from a number of countries. 

In the hemorrhagic stroke session, Dr. Song Lili, Head of the Stroke Research Program and Senior Research Fellow at The George Institute China, gave a speech entitled “Prognostic significance of abnormal physiological variables cluster in acute ICH: INTERACT2 study” at the conference and shared the results of the secondary analysis of the INTERACT2 trial.  The study confirmed a strong correlation between a cluster of four physiological parameters of blood pressure, blood glucose, body temperature, and history of antithrombotic drugs, on adverse outcomes in strokes due to hemorrhage.  These data provide a strong basis for the new research project, INTERACT3, which Dr. Song introduced and aroused great interest from the audience.  After the meeting, authoritative Professors in cerebral hemorrhage took the opportunity to discuss these findings and the INTERACT3 project with Dr. Song.  Some also wanted to participate in the study.

INTERACT3 is a collaboration between clinical researchers at West China Hospital, Chengdu and The George Institute, China.  It aims to establish the effects of ‘care bundle’ involving the early use of intensive BP lowering, control of glucose and fever, and correction of anticoagulation, as compared to routine care.  The study is a quality improvement, implementation study, that uses a novel, stepped wedge, cluster design across hospitals in China and overseas.  Currently, INTERACT3 is being carried out in 45 hospitals in China, and 800 patients have been enrolled. 

Dr. Wang Xia, Senior Research Fellow at The George Institute for Global Health, Australia gave a presentation on her poster “An individualised decision making tool for use of low versus standard dose alteplase in acute ischemic stroke”.  These data were from the ENCHANTED clinical trial, to calculate a model that can be used to evaluate which patients may benefit more than others from the use of low-dose thrombolysis ‘clot-busting’ treatment (tPA), to help clinicians to make more informed choices for this treatment, which carries a risk of serious hemorrhage, in patients with acute stroke due to a blocked blood vessel in the brain, called cerebral infarction.  Research to guide clinical practice is a mission of The George Institute, recognized by experts at home and abroad, and aroused positive discussion among participants at the conference.